SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to optimism surrounding upcoming data presentations at the World Muscle Society Congress, with the community anticipating positive results and potential label expansion for ELEVIDYS. Discussions also involve potential short squeezes and renewed investor confidence, with some speculating on a possible buyout. The community is focused on key presentations and data releases throughout the week.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending due to investor concern surrounding a lock-up expiry potentially flooding the market with new shares, leading to price dips. The community is debating whether this presents a buying opportunity or signals further decline, with some drawing comparisons to $HOOD's past performance and others pointing to short interest. Discussions also involve the company's management and the potential for dilution.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

$TMC is trending as the deep-sea mining sector gains traction, with community members discussing potential short squeezes and a possible breakout. Optimism is fueled by anticipation of government partnerships and regulatory approvals, particularly the NOAA decision. Bullish investors are focused on the company's long-term potential in the critical minerals market.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending due to new multi-year AI cloud contracts, specifically related to NVIDIA Blackwell GPUs, with the community buzzing about the company's strategic pivot and potential for significant revenue growth. Bullish sentiment surrounds the contracts' average 2-year terms and 2-year payback, suggesting strong demand, while some analysts debate valuation amid the AI infrastructure race. The conversation also includes comparisons to peers and speculation about future partnerships.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending amid speculation about an undisclosed institutional investor who made a $75M private placement, boosting the company's AI connectivity solution prospects. The community is buzzing with possibilities, with NVIDIA being a popular guess due to POET's optical tech relevance for GPU clusters, and the reveal of the investor expected around Oct 17. Bullish sentiment is fueled by potential short and gamma squeezes as well as strong partnerships.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending as spot gold prices surge, driven by safe-haven demand amid economic uncertainty and a potential government shutdown. Community discussions revolve around gold's breakout above $4,000/oz and whether this rally is sustainable or indicative of a larger market bubble. Some analysts suggest gold's rise signals underlying economic concerns, while others point to central bank buying and a weakening dollar as key catalysts.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape ($QS) is trending as investors speculate on potential OEM partnerships, particularly with Tesla and Toyota, following Murata's announcement about scaling high-volume separator production. Community discussions revolve around the company's solid-state battery technology and its potential to disrupt the EV battery market, with some highlighting government support and growing lithium production in the US as tailwinds. Bullish sentiment is fueled by anticipation of new deals and upcoming earnings, while bears cite potential delays in commercialization and the company's cash burn rate.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

GLTO is trending due to a speculative surge, drawing comparisons to SPRB's previous move and generating significant community buzz around potential gains. Traders are actively discussing short squeezes and technical setups, while also debating the sustainability of the stock's momentum. The stock's low float is a key factor in discussions, with some suggesting further upside potential.

Confluent, Inc. engages in creating a data infrastructure platform focused on data in motion. The firm provides application architecture engagement, multi data center, security and upgrade engagement, and Amazon web services cloud deployment services. Its products include Confluent Cloud, Confluent Platform, WarpStream BYOC, Connectors, Flink, Stream Governance, and Confluent Hub. The company was founded by Edward Jay Kreps, Neha Narkhede, and Jun Rao on September 1, 2014, and is headquartered in Mountain View, CA.

Confluent Inc - Ordinary Shares Class A

Confluent Inc

CFLT is trending due to speculation around a potential buyout, with names like SNOW and Databricks mentioned as possible suitors. The community is actively discussing call option flow and potential breakout opportunities, while also noting the company's potential in data streaming for agentic AI. Some investors express frustration with management and past performance, while others see the stock as undervalued with strong long-term potential.

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

AlphaTON Capital Corp.

AlphaTON Capital Corp. ($ATON) is trending due to a surge in interest following news related to its digital asset treasury focused on the TON blockchain. Community members are discussing the company's potential as a runner, citing its low float and key management, including executives with experience at NASDAQ and Cambridge Analytica, while drawing comparisons to other recent high-momentum stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NewAmsterdam Pharma Company N.V. (NAMS) Soars 5.9%: Is Further Upside Left in the Stock?

NewAmsterdam Pharma Company N.V. (NAMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates

NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of +71.15% and +486.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.

NewAmsterdam Pharma Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma

TD Cowen Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on NewAmsterdam Pharma Company (NAMS Research Report). The comp...

Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results

NewAmsterdam Pharma announced positive topline results from the Phase 3 BROOKLYN trial for obicetrapib, showing a significant LDL-C reduction in HeFH patients. The stock fell 8.35% despite the...

RBC Capital Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)

RBC Capital analyst Leonid Timashev maintained a Buy rating on NewAmsterdam Pharma Company (NAMS Research Report) yesterday and set a price targe...

Piper Sandler Sticks to Its Buy Rating for NewAmsterdam Pharma Company (NAMS)

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on NewAmsterdam Pharma Company (NAMS Research Report) today and set a price target o...

NewAmsterdam Pharma Announces Executive Leadership Changes

An announcement from NewAmsterdam Pharma Company (NAMS) is now available. NewAmsterdam Pharma Company N.V. has announced Juliette Audet's new role...

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company NV

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$32.21
Prev Close	$32.48
Open	$32.12
Dividend Yield	0.00%
50-Day Moving Average	$25.42
Beta	0.77
Avg. Volume	1.01M
PE Ratio	-20.14

52-Week High	$34.62
52-Week Low	$14.06
Market Capitalization	$3.66B
EPS (Annual)	-$2.56
Price to Book	4.69
Revenue Per Employee	$670,044.12
Enterprise Value/EBITDA	N/A

NAMS NewAmsterdam Pharma Company NV

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NAMS News